Investigating antibody reactivity to the intestinal microbiome in severe

- 2 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
- 4 Katharine A. Seton¹, Marianne Defernez¹, Andrea Telatin¹, Sumeet K. Tiwari¹,
- 5 George M. Savva¹, Antonietta Hayhoe¹, Alistair Noble³, Ana Carvalho⁴, Steve
- ⁶ James¹, Amolak Bansal⁵, Thomas Wileman^{1,2} and Simon R. Carding^{1,2}
- 8 ¹Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK
- 9 ²Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK
- 10 ³The Pirbright Institute, Woking, GU24 0NF, UK
- ⁴Experimental Arthritis Treatment Centre for Children, University of Liverpool, Liverpool,
- 12 L12 2AP

14

15

1

3

- 13 ⁵Spire St Anthony's Hospital, Surrey, SM3 9DW, UK
- 16 Corresponding author:
- 17 Prof. Simon R. Carding
- Food, Microbiome and Health Research Programme
- 19 Quadram Institute Bioscience
- 20 Norwich Research Park
- 21 Norwich, NR4 7UQ
- 22 U.K.
- 23 (e) simon.carding@quadram.ac.uk

Abstract

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

44

45

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystemic disease of unknown aetiology that is characterised by disabling chronic fatigue and involves both the immune and gastrointestinal (GI) systems. Patients display alterations in GI microbiome with a significant proportion experiencing GI discomfort and pain and elevated blood biomarkers for altered intestinal permeability compared with healthy individuals. To investigate a possible GI origin of ME/CFS we designed a feasibility study to test the hypothesis that ME/CFS pathogenesis is a consequence of increased intestinal permeability that results in microbial translocation and a breakdown in immune tolerance leading to generation of antibodies reactive to indigenous intestinal microbes. Secretory IgA and serum IgG levels and reactivity to intestinal microbes were assessed in five pairs of severe ME/CFS patients and matched same-household healthy controls. For profiling serum IgG we developed IgG-Seq which combines flow-cytometry based bacterial cell sorting and metagenomics to detect mucosal IgG reactivity to the microbiome. We uncovered evidence for immune dysfunction in severe ME/CFS patients that was characterised by reduced capacity and reactivity of serum IgG to stool microbes, irrespective of their source. This study provides the rationale for additional studies in larger cohorts of ME/CFS patients to further explore immunemicrobiome interactions.

43 Keywords: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), antibodies,

immunoglobulin G, immunoglobulin A, microbiome, autologous, heterologous, immune tolerance,

leaky gut.

Introduction:

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterised by disabling fatigue and autonomic, muscular, cognitive, neurological and immune symptoms that leave patients unable to undertake their pre-morbid work, education, exercise and social activities¹. A quarter of diagnosed patients are house- or bedbound² and less than 5% ever recover their pre-morbid activity levels³. A meta-analysis based on 45 studies estimated an average population prevalence of 0.68% (95%CI = 0.48 to 0.97) ⁴. However, these estimates vary considerably by population and case definition⁴. The prevalence is anticipated to rise following the COVID-19 pandemic as 45.2% of long COVID patients fulfil ME/CFS diagnostic criteria⁵. The most common trigger of ME/CFS is an infection, while other reported triggers include physical or mental trauma and toxin exposure³.

Several factors have been implicated in ME/CFS pathogenesis involving the immune (autoimmunity, inflammation and chronic infection), gastrointestinal (GI), neurological, endocrine and metabolic systems⁶. Between 38 and 92% of ME/CFS patients report comorbid GI disturbances such as IBS^{3,7-9} and 35% of patients take medication for GI disturbances including pro- and prebiotics, digestive enzymes and sodium bicarbonate³. The high co-occurrence of ME/CFS and IBS suggests possible involvement of the intestinal microbiome. Consistent with this possibility several studies have reported changes in the community structure of the stool microbiome of ME/CFS patients exemplified by reduced diversity⁸ and decreased abundance of short-chain fatty acid producing bacterial species⁸⁻¹². ME/CFS patients may also have elevated biomarkers associated with increased intestinal permeability^{8,13,14}. Intestinal inflammation and increased permeability can compromise immune and microbial tolerance (defined as a state of hypo responsiveness to autologous intestinal microbes) ¹⁵ leading to hyperreactivity and serum antibody production to autologous intestinal microbes¹⁶; this can pre-stage autoimmune disease¹⁷. Of note, ME/CFS

patients displaying increased intestinal permeability have a higher incidence of serotonin autoimmunity¹⁸.

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Based upon these observations we hypothesised that ME/CFS pathology is a consequence of the breakdown in immune tolerance resulting from the increased intestinal permeability and microbial translocation that leads to generation of antibodies reactive to autologous intestinal microbes. In support of this proposal, a previous study found that, compared with healthy controls, ME/CFS patients had abnormally high levels of IgA and IgM produced in response to a panel of seven gram-negative enterobacteria¹³. However, this small panel of microbes does not reflect the complexity of the intestinal microbiota which comprises 300-500 bacterial species as well as viruses, archaea and fungi¹⁹. In addition, IgM antibodies have low specificity for antigens²⁰ and IgA is primarily produced at mucosal sites²¹. Serum IgG reactivity to the microbiome in ME/CFS patients has recently been investigated using phage immunoprecipitation sequencing (PhIP-Seq) to screen IgG reactivity to 244,000 bacterial and viral epitopes²². This study is, however, restricted to identifying antibody reactivity to peptide antigens and cannot detect reactivity to the immunogenic glycoproteins and lipoproteins that decorate the outer membrane and surface of bacterial cells, viruses and fungi²³. Furthermore, none of the approaches used to date provide information on whether immune tolerance to indigenous intestinal microbes is lost in ME/CFS.

To begin to address this important question and assess the systemic humoral immune response to indigenous microbes we adapted 'IgA-Seq', a method that combines flow-cytometry-based bacterial cell sorting and 16S rRNA sequencing to detect mucosal IgA reactivity to the microbiome²⁴, to characterise serum IgG reactivity to the microbiome; we refer to this new method as IgG-Seq. To evaluate the IgG-Seq protocol, we designed a feasibility study with a small cohort of severe ME/CFS patients and healthy controls from the

same households. The difficulty in accessing housebound or bedbound patients is a major obstacle to understanding the pathophysiology and aetiology of ME/CFS and is why only 0.5% of ME/CFS research is undertaken in severely affected patients². One aim of this study, therefore, was to assess the feasibility of, and barriers to, including severe ME/CFS patients in research involving the collection of biological samples.

Results:

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

Recruiting severe ME/CFS patients and same household controls

Study participants were recruited from the CFS clinic at Epsom and St Helier University Hospitals (ESTH), Carshalton, UK and the ME/CFS service at East Coast Community Healthcare Centre, Lowestoft, UK which together had 3,812 registered patients. Recruitment began in October 2017, with the intention of recruiting ten severe house- or bedbound ME/CFS patients and ceased in April 2020 due to the COVID-19 pandemic. Thirty-six patients were invited to the study with a response rate of 58.3% (Supplementary Fig. S1). Of those who responded, 42.9% were ineligible due to either the absence of a household control (n = 4), failure to meet other inclusion criteria (n = 4) or were unable to provide written informed consent (n = 1). Of the 12 eligible pairs of participants, six provided informed consent. The consenting appointments for the other six eligible participants were delayed either due to patients rescheduling their appointments when feeling unwell, or the nonavailability of phlebotomists to attend home visits. Consequently, consenting appointments were delayed by up to 12 months for participants, by which point three patients either saw their health further deteriorate preventing them from participating in the study, or acquired an additional health complication that excluded them from the study. We received no further communication from the remaining three pairs.

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

Study population characteristics Samples were collected from five pairs of participants; one pair consented immediately prior to the COVID-19 pandemic which prevented us from obtaining their samples (Table 1). The recruited patients comprised four females and one male (mean age 33.8 years; standard deviation (SD) 13.8). There was clinical heterogeneity amongst patients, with variation in the age at which ME/CFS onset occurred, length of illness and symptom severity. Three patients reported ME/CFS onset following a viral infection, one following vaccination and one following surgery. IBS was reported in all patients but in none of their matched household controls. Same household healthy controls included four males and one female (mean age 40.4 years; SD 16.7) who were the carers and spouse (n = 3), parent (n = 1) or sibling (n = 1)of the patients. Stool consistency does not separate severe ME/CFS patients with IBS from matched household controls without IBS Despite all ME/CFS patients, and no household controls, reporting IBS there was no evidence for a difference in consistency of the collected stool samples between patients and controls, as measured by the Bristol stool form scale (BSFS) or by water content (Fig. 1A and 1B). Three controls had abnormally loose stools (BSFS 5-7) indicative of diarrhoea and one control had an abnormally hard stool (BSFS 2) indicative of constipation. In contrast, two patients had stool samples defined as having a healthy consistency (BSFS 3-4), one patient had an abnormally loose stool (BSFS 5) and two patients had abnormally hard stools (BSFS 1-2).Assessment of secretory IgA in stool The concentrations of microbe bound IgA1/2 (Fig. 2A) and free IgA1/2 (Fig. 2B) were measured by ELISA with no evidence of a significant difference between severe ME/CFS

patients and their matched household controls. Flow cytometry was used to determine the distribution of IgA coating on stool microbes (Fig. 3A and 3B). When comparing the proportion of stool microbes coated by IgA there was no evidence of any differences between patients and matched controls (Fig. 3C). Based on the microbial load of stool samples (Supplementary Fig. S2) the relative quantification of IgA bound microbes was converted to absolute values which again revealed no evidence of differences between patients and matched controls in the quantity of IgA coated microbes within stool samples (Fig. 3D).

Severe ME/CFS patients have a reduced serum IgG immune response to stool microbes

To determine whether immune tolerance to intestinal microbes was altered in severe ME/CFS patients the level of serum IgG antibodies bound to both their own (autologous) stool microbes and to non-self (heterologous) stool microbes from other individuals were measured in patients and their matched household controls (Fig. 4A). Four patients had lower serum IgG reactivity to indigenous stool microbes than their matched household controls (p =

0.07322) and all patients had lower serum IgG reactivity to foreign stool microbes than their

matched household controls (p = 0.006334) (Fig. 4B). Furthermore, there was evidence for

controls having higher serum IgG reactivity to heterologous (patient) stool microbes than

serum IgG reactivity to autologous stool microbes (p = 0.0317). In contrast, for patients there

was no evidence for a difference in serum IgG reactivity to autologous and heterologous

(control) stool microbes (p = 0.3619). In addition, serum IgG reactivity to patients

(heterologous) stool microbes in control individuals was higher than serum IgG reactivity to

autologous stool microbes in patients (p = 0.003751). A paired t-test of the averaged IgG

levels to indigenous and foreign stool microbes within individuals suggests that patients had a lower IgG reactivity to stool microbes than controls irrespective of the source of the microbes (p=0.0185). Of note, the reduced levels of patient IgG antibodies to indigenous and foreign

stool microbes were not due to lower levels of serum IgG in patients (Fig. 4C).

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

The proportion of microbes bound by serum IgG is high in both patients and controls We next sought to determine how much of the stool microbiome was recognised by serum IgG by measuring the proportion of indigenous stool microbes coated by serum IgG (Fig. 5A) and 6B). There was no evidence for any differences in the proportion of stool microbes coated by IgG ('IgG positive') in severe ME/CFS patients compared with controls (Fig. 5C). Characterising the stool microbiome Using whole metagenome shotgun sequencing the microbial composition of SYBR Green⁺ ('all') stool microbes isolated by fluorescent activated cell sorting (FACS) was determined (Supplementary Fig. S3). The average number of 'all' microbes collected by FACS was 1.47 million. Taxa with a relative abundance greater than 1 x 10⁻⁶ were included in downstream analyses and comparisons made at the genus and species level. At the genus level 275 taxa were detected. The 15 most abundant genera across all ME/CFS and matched household control samples (n = 10) were *Bacteroides* (10.4%), Phocaeicola (10.1%), Clostridioides (9.5%), Lysobacter (9.4%), Faecalibacterium (8.6%), Blautia (7.1%), Roseburia (5.8%), Anaerostipes (5.5%), Akkermansia (4.4%), Campylobacter (2.9%), Agrobacterium (2.6%), Methanobrevibacter (1.9%), Bifidobacterium (1.9%) Anaerobutyricum (1.5%) and Streptococcus (1.3%) (Supplementary Fig. S3A). At the species level 705 taxa were detected. The 15 most abundant species across all ME/CFS and matched household control samples (n = 10) were Clostridioides difficile (9.5%), Lysobacter enzymogenes (9.4%), Faecalibacterium prausnitzii (8.6%), Phocaeicola dorei (6.4%), Blautia sp. SC05B48 (6.3%), Anaerostipes hadrus (5.4%), Roseburia intestinalis (4.5%), Akkermansia muciniphila (4.3%), Bacteroides uniformis (3.7%), Phocaeicola vulgatus (3.6%), Agrobacterium tumefaciens (2.5%), Methanobrevibacter smithii (1.8%), Bacteroides cellulosilyticus (1.6%), Anaerobutyricum hallii (1.5%) and Campylobacter jejuni (1.5%) (Supplementary Fig. S3C).

Using three measures of intra-sample diversity, the Shannon index, inverse Simpson index and observed richness, there was no evidence for differences in any of the alpha diversity measures between severe ME/CFS patients and matched household controls at the species level (Supplementary Fig. 4A).

Due to the large variation in microbial load in stool samples from severe ME/CFS patients (6.3 x 10¹⁰ cells/gram to 2.6 x 10¹¹ cells/gram) and controls (1.2 x 10¹¹ cells/gram to 2.0 x 10¹¹ cells/gram) (Supplementary Fig. S2), converting relative abundances to absolute abundances increased the heterogeneity amongst samples at both the genus and species levels (Supplementary Fig. S3B and S2D). However, analysis of beta diversity using Bray-Curtis dissimilarity identified subtle changes in both relative microbiome profiles (RMP) and quantitative microbiome profiles (QMP). Samples from patients in pairs three, four and five were most dissimilar to the other samples while samples from patients in pairs one and two clustering together with their matched household controls (Supplementary Fig. S4B).

Functional differences in the microbiome of patients and controls were determined by comparing the abundance of gene families in the 'all' fraction. A total of 464,263 gene families were detected in all participants above the threshold. A further filtering step removed gene families below the threshold in more than seven samples, leaving 84,888 gene families for evaluation. PCA was used to reduce the number of variables by defining principal components (PC) that highlighted the largest sources of variation amongst the samples. PC4 identified 11% of variation in functional genes families amongst samples that were attributable to disease status (Supplementary Fig. S5).

IgG-Seq identifies antimicrobial signatures unique to each participant

Next, IgG-Seq was used to characterise the indigenous gut microbes bound by serum IgG in severe ME/CFS patients and matched household controls. Briefly, 'IgG positive' and 'IgG negative' microbes were isolated by FACS from bulk stool samples and processed for shotgun metagenomic sequencing to identify taxa preferentially bound by serum IgG (Fig. 6A and 6B). The mean number of 'IgG positive' microbes collected by FACS was 1.05 x 10⁶. The mean number of 'IgG negative' microbes isolated by FACS was 1.30 x 10⁶. Taxa with a relative abundance greater than 1 x 10⁻⁵ in the 'all' fraction were included in the 'IgG positive' and 'IgG negative' fractions for downstream analyses. Taxonomic comparisons were made at the species level.

Observed richness scores were applied to rarefied reads to determine the number of microbial species with serum IgG reactivity (Fig. 6C). All participants had more than 200 species in the 'IgG positive' fraction with a high number of species also identified in the 'IgG negative' fraction. Both patients and controls had a higher mean number of species in their 'IgG negative' fraction than their 'IgG positive' fraction (365 vs 339 in patients and 358 vs 322 in controls). However, most participants had a small number of species (<30) exclusively in the 'IgG negative' fraction at a relative abundance >1 x 10⁻⁵, except for the patient from pair three who had 107 species exclusively in their 'IgG negative' fraction (Table 2). In addition, this patient also had a smaller proportion of species recognised by IgG compared with all other participants (Table 2).

Next, we assessed the similarity/difference between 'IgG positive' and 'IgG negative' fractions in patients and controls using the Bray-Curtis index and visualising distances using an NMDS plot (Fig. 6D). 'IgG positive' and 'IgG negative' fractions from the same participant shared the greatest similarity. No clustering was seen for either fraction in patients or controls. The 'IgG positive' and 'IgG negative' fractions from patients in pairs three and five were most dissimilar to the other samples.

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Using the probability ratio developed by Jackson et al., (2021) 25 we scored IgG binding by directly measuring the likelihood of a species being bound by IgG. Positive IgG probability ratios indicate that a species is more likely to be coated with IgG and reside in the 'IgG positive' fraction. Conversely, negative IgG probability ratios indicate that a species is more likely to be uncoated and reside in the 'IgG negative' fraction. Probability ratios are not influenced by the relative abundance of a species within the 'all' fraction and therefore measure the quantity of IgG produced against a given species. Of the 423 species detected at a relative abundance greater than 10⁻⁵, 101 species were detected in every participant and therefore used in downstream analysis. It is worth noting that despite detecting species falling into the bacteria, fungi, archaea and virus kingdoms, only bacterial species were detected in every participant and consequently used in downstream analysis. Notably, owing to the way in which probability ratios are calculated they tend to be similar across species within participants, with some having consistently lower estimates across all species than others, driven by their overall IgG probability ratio. Probability ratio scores varied amongst species and participants. Each participant had a unique combination of probability ratio scores for different species (Fig. 7). We were unable to meaningfully test for differences in probability ratio scores between patients and controls for individual species due to the small sample size and lack of power to detect significant changes.

Finally, we analysed the function of the microbial communities within the 'IgG positive' and 'IgG negative' fractions by analysing the likelihood of a gene family being present in a microbe bound by IgG. IgG probability ratios were calculated for the 1724 gene families that were detected in all participants above the threshold. Using a PCA plot to assess how the ten samples varied with regards to the likelihood of certain gene families being present in microbes bound by IgG (Supplementary Fig. S6), a separation between severe

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

ME/CFS patients and controls from four households was observed (PC2), corresponding to 13% of explained variance. **Discussion:** This feasibility study highlights the logistical challenges of including severe, house- or bedbound ME/CFS patients in research studies and collecting biological samples. Contrary to our initial hypothesis, our findings from a small cohort of patients and controls suggests that severe ME/CFS patients may have a reduced serum IgG immune response to stool microbes. Lessons learnt for the inclusion of severe ME/CFS patients in biomedical research Despite their significant disability severe ME/CFS patients were enthusiastic and eager to participate in our study with a 58% response rate. However, severe ME/CFS often coincided with additional illness complications that excluded these individuals from the study, hindering recruitment. We also found that symptom severity of house- or bedbound ME/CFS patients fluctuated, making it difficult to arrange home study visits. The wide geographical distribution of participants' homes (30 – 140 miles from the research institute) restricted sample collection with a minimum of two hours required for sample collection and transportation to the laboratory. We recruited controls from the same household as the patient to account for environmental confounders of microbiome analyses such as living conditions and diet^{26,27}. Previous studies have shown that inclusion of same household controls enables identification of ME/CFS disease-specific microbiome changes²⁸. However, the requirement for a matched healthy household control impacted on patient recruitment. Amongst patients not meeting the study eligibility criteria, 44% were excluded due to being unable to identify a matched household control. Considering that household controls were typically carers and parents or spouses of the patient, it was not possible to match age and gender of patients and controls, both of which are confounding variables for immunological^{29,30} and microbiome studies³¹. Other confounders potentially discordant amongst patients and controls were BMI, exercise and medications. Our finding of a sparse clustering between results from severe ME/CFS patients and matched household controls suggests that these and perhaps other confounding variables had an influence on immune response to the intestinal microbiome. Future studies should consider including and accounting for as many of these confounding variables in analysis as possible.

Severe ME/CFS patients have serum IgG hyporeactivity to stool microbes

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

The hypothesis guiding our study was that ME/CFS patients have increased intestinal permeability due to an altered microbiome, which results in translocation of intestinal microbes into the circulation, triggering an immune response. Despite the low study sample size, we found evidence that severe ME/CFS patients in fact have lower serum IgG levels reactive to stool microbes than their matched household controls. This appears to be a property of the patients' immune responses, rather than their microbiome which structurally and functionally closely resembled that of their matched controls. Our findings mirror the findings from pioneering studies investigating immune reactivity to faecal microbes in IBD patients which demonstrated that healthy controls have higher serum IgG reactive to heterologous stool microbes than to autologous stool microbes¹⁵. In our study heterologous reactivity was measured using samples from individuals living in the same household which are known to display greater similarity to patients' microbiomes than individuals living in different households³². This should increase confidence in identifying microbes that distinguish the microbiome of patients from controls as being a property of the disease. Despite this advantage there were no differences in alpha diversity measures between severe ME/CFS patients and matched household controls at the genus or species level. Instead, our findings provide initial evidence for immune dysfunction in ME patients manifesting as a reduced capacity and reactivity of serum IgG to stool microbes irrespective of their source. Previous studies have described IgG immunodeficiencies in ME³³ which could explain why we found reduced levels of serum IgG binding to stool microbes in severe ME/CFS patients. However, there was no evidence of IgG immunodeficiencies in our severe ME/CFS patient cohort. Instead, it may be attributable to IgG antibody repertoires and a less diverse repertoire of antibodies directed at intestinal microbes. The loss of antibody diversity occurs naturally during ageing and is a defining feature of immune senescence and declining immune function in later life³⁴. The possibility of premature or accelerated immunosenescence should be a focus of future studies, particularly as it relates to effector immune cells whose functionality is compromised in ME patients, as previously described for NK cells³⁵, and here for B cells. An additional possibility relates to immune hibernation in ME/CFS patients which produces a hypometabolic state³⁶ that may limit lymphocyte responsiveness to foreign antigens and increased tolerance to bacterial endotoxins³⁷.

Limitations of the study in addressing the study hypothesis

The severe ME/CFS patients recruited to this pilot study had comorbid IBS, whereas household controls were free of any GI complaints. IBS comorbidity is a confounding variable in ME/CFS microbiome studies as defined microbiome profiles have been described that discriminate between patients with and without IBS comorbidity⁹. To establish whether the results found in this pilot study of severe ME patients are disease specific future studies should compare severe ME/CFS patients with and without comorbid IBS and compare severe ME/CFS patients with comorbid IBS to IBS patients.

We were unable to confirm the presence of increased intestinal permeability within the severe ME/CFS patient cohort. Based upon previous studies most ME patients (~67%)

will have increased intestinal permeability compared with healthy controls¹³. An intact intestinal barrier in the severe ME/CFS patients recruited to this study might explain why they did not have increased IgG reactivity to autologous stool bacteria compared with their matched healthy household controls. It has been shown that levels of IgG reactive to autologous stool bacteria are elevated in other diseases associated with increased intestinal permeability such as Crohn's disease¹⁶. Future studies should seek to establish the integrity of the intestinal barrier in severe ME/CFS patients.

The IgG-Seq protocol used in this research identified serum IgG produced in response to bacteria and fungi. Whilst excluding reactivity to other constituents of the intestinal microbiome in the current study, the method can be adapted to detect IgG reactivity to viruses and archaea that can then be identified and isolated using FACS.

Conclusion

Severe ME patients have historically been excluded from research studies. This pilot study demonstrates the feasibility and challenges associated with including this important and growing population of ME patients in research. In providing evidence of immune dysfunction in severe ME/CFS patients, expressed as hyporesponsive serum IgG responses to intestinal microbes, this study also provides the theoretical and methodological basis and rationale for undertaking more detailed immune function studies in larger cohorts of ME patients.

Patients and Methods

Participant recruitment

Ten volunteers were enrolled onto this study between 2018 and 2019: Five severe ME/CFS patients and, as controls, five healthy individuals that were the patients' carers and living in

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

the same household. Severe ME/CFS participants were recruited by the tertiary referral centres Epsom and St Helier University Hospitals (ESTH) CFS Service, Carshalton, UK, and the East Coast Community Healthcare Centre (ECCHC) ME/CFS service, Lowestoft, UK. All severe ME/CFS patients had a confirmed diagnosis of ME/CFS based on a hybrid of the NICE 2007 guidelines³⁸ and the CDC-1994 criteria³⁹ and defined as experiencing at least four of the following symptoms for a minimum of 4 months; cognitive difficulties, muscle pain, multi-joint pain, new headaches, recurrent sore throats, cervical/axillary lymphadenopathy, unrefreshing sleep and post exertional malaise. Severity was based on being unable to undertake activities associated with daily living, wheelchair dependency for mobility and being house- or bedbound and requiring aid for washing, using the toilet and eating. All patients were asked to complete the Chalder fatigue questionnaire, shortened medical outcomes study 36-item short form health survey (SF-36), hospital anxiety and depression scale (HADS), a self-efficacy questionnaire, visual analogue pain rating scale and the Epworth sleepiness scale. Matched household controls were defined as individuals who were living with or caring for the severe ME/CFS patient. Matched household controls were excluded if they had a long-term medical condition, in particular gastrointestinal conditions, autoimmune diseases, anxiety, or depression; or were receiving immunomodulatory drugs, statins, beta blockers or steroids. Participants consuming antibiotics or probiotic capsules within the 6 weeks prior to sample collection were excluded.

The study was performed in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice (ICH GCP) Guideline, and in compliance with national law. The research was approved by the NHS Health Research Authority London Hampstead Research Ethics Committee (REC 17/LO/1102, IRAS ID 218545). This study was registered on the clinicaltrials.gov database (NCT03254823). All participants provided fully informed written consent. The collection,

storage and use of human tissue samples was carried out within the terms of the Human

Tissue Act 2004 (Human Tissue Authority).

Sample collection and processing

Fresh stool and blood samples were collected from each participant within a 24 h window during a home visit. Twenty millilitres of blood were collected in serum separator tubes (BD Vacutainer). Serum was separated from whole blood following the manufacturers protocol and immediately stored at -80°C. Stool samples were collected immediately after defecation in a Fecotainer® (AT Medical BV) with an OxoidTM AnaeroGenTM compact sachet (Thermo Scientific) to preserve anaerobic bacteria. The consistency and appearance of fresh stool samples was recorded using the Bristol stool form scale (BSFS) ⁴⁰. Stool samples were stored at 4°C for <24 h. Following homogenisation aliquots of the bulk homogenate and of 40% stool microbial glycerol suspensions were stored at -80°C. Glycerol stocks were prepared by diluting stool samples (10% w/v) with PBS, collecting the supernatant following centrifugation at 300g for 5 min at 20°C and diluted 1:1 with 80% v/v glycerol.

Stool water content

Non-diluted aliquots of stool were weighed before and after freeze drying using the ModulyoD freeze dryer (Thermo Electron Corp.) for 12 h. Water content was calculated using the following equation.

$$\frac{(wet\ weight-dry\ weight)}{wet\ weight}\times 100$$

Stool microbial load

Non-diluted stool aliquots were thawed on ice and diluted (1% w/v) with PBS solution containing 0.1% w/v BSA fraction V. Samples were homogenised using a KimbleTM KontesTM Pellet PestleTM Cordless motor and filtered through a 70 µm cell strainer. Filtered

microbial suspensions were diluted 1:1600, 1:3200 and 1:6400; then 200μl of each dilution were incubated with 10μl of 1:100 SYBRTM Green I nucleic acid gel stain (Thermofischer Scientific) for 30 min. Microbial load was determined using the Guava® easyCyteTM 5HT equipped with a 488 nm laser. Prior to sample acquisition the instrument was cleaned following manufacturers' instructions and calibrated using the Guava® easyCheckTM kit. Stool microbes (SYBR Green+ events) were enumerated using Guava® Suite Software v3.3.

Stool IgA concentration

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

Non-diluted stool aliquots were thawed on ice, diluted (10% w/v) with 0.2M NaHCO₃, pH 9.4 and homogenised using a KimbleTM KontesTM Pellet PestleTM Cordless motor. Samples were centrifuged twice at 16,000g for 5 min at 20°C and after both rounds of centrifugation the pellet and supernatant were separated. The supernatants were pooled and used to analyse free secretory IgA (sIgA) by ELISA. The pellet was washed and resuspended to the original volume and used to analyse microbe associated/bound sIgA by ELISA. All reactants except for the blocking solution and wash buffers were added in volumes of 100 µl/well. All washes were repeated three times with PBS and 0.05% TweenTM 20 unless otherwise stated. Nunc MaxiSorpTM flat-bottom plates (Thermo Fisher Scientific) were coated for 16h at 4°C with 10-fold serial dilutions (1 to 1:1000000) of samples and with 2-fold serial dilutions (250-3.9 ng/ml) of a human colostrum IgA standard (Sigma), diluted with 0.2M NaHCO₃, pH 9.4. Samples and standards were plated in duplicate. Plates were washed and then blocked for 3h with 300µl/well of PBS, 0.05% TweenTM 20, 2% BSA fraction V, 1% normal mouse serum (Thermo Fisher Scientific). Plates were washed and then incubated with 1000 ng/ml biotin conjugated mouse anti-human IgA1/IgA2 monoclonal antibody (Pharmingen) diluted in PBS, 0.05% TweenTM 20, 2% BSA fraction V, 1% normal mouse serum. After 1h of incubation at 20°C plates were washed and incubated with 1:80000 HRP-Conjugated Streptavidin (Thermo Fisher Scientific) diluted in PBS, 0.05% Tween™ 20, 2% BSA fraction V, 1% normal mouse

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

serum for 30 min at 20°C. Plates were washed six times and incubated with TMB high sensitivity substrate solution (BioLegend® UK Ltd) for 5 min. The addition of 2N H₂SO₄ stopped the reaction and absorbances were read at 450 nm. IgA sample values were determined by reference to standard curves. Serum IgG quantification Total serum IgG was measured using the commercial Invitrogen ELISA kit (Thermo Fisher Scientific). Samples were measured in duplicate. Serum IgG levels to autologous and heterologous stool microbes Glycerol stocks of stool microbes were thawed and washed three times with PBS at 8000g for 5 min at 20°C. The pellet was resuspended in 1ml PBS. Serial dilutions (2-fold) of stool microbes in PBS were plated in duplicate in a 96-well flat bottom CorningTM CostarTM 9018 plate. Absorbances were read at 570 nm and stool microbes were resuspended to an optical density of 0.05 with 0.1M NaHCO₃, pH 9.4. Serum IgG reactivity to autologous ('self') or heterologous ('non-self', matched patient or control) stool microbes was measured by ELISA. All washes were repeated three times with 200 µl/well PBS and 0.1% TweenTM 20 unless otherwise stated. Nunc MaxiSorpTM flat-bottom plates (Thermo Fisher Scientific) were coated for 16h at 4°C with 100 µl/well of stool microbes. Plates were washed and then blocked for 3h at room temperature under agitation with PBS, 2% BSA fraction V, 1% normal goat serum (Sigma-Aldrich). Plates were incubated for 1 h at 20°C with 50 µl/well of complement inactivated serum samples 2-fold serially diluted (1:80-1:320) in PBS, 2% BSA fraction V, 1% normal goat serum. Plates were washed and incubated for 1h at room temperature under agitation with 100 μl/well of 1:500 goat anti-human IgG H&L (HRP) (Abcam,) diluted in PBS, 2% BSA fraction V, 1% normal goat serum. Plates were washed six times and incubated with TMB high sensitivity substrate solution (BioLegend® UK Ltd) for 5 min at 20°C. The addition of 0.16M H₂SO₄ stopped the reaction and absorbances were read at 450 nm. Results were normalised by subtracting serum only absorbance readings from sample readings.

Microbial flow cytometry

Systemic IgG and faecal IgA binding to stool microbes was assessed by microbial flow.

cytometry. All buffers were filter sterilised using a 0.22-um filter before use. Aliquots of non-diluted stool samples were processed and the microbial concentration in each stool sample measured as described earlier. Microbes were resuspended to 2 x 10⁶ cells/ml in PBS with 0.1% BSA. 500µl of complement inactivated serum was diluted 1:100 in PBS with 0.1% BSA and incubated for 30 min at 20°C with 200 µl of 1 x 10⁶ cells/ml of stool microbes. For secretory IgA measurements stool microbes were not incubated with serum. Samples were washed in PBS with 0.1% BSA (5 min, 1.2 x 10⁴ rpm) and microbes were resuspended to 1 x 10⁶ cells/ml and incubated with 1:1000 SYBRTM Green I nucleic acid gel stain and 1:100 secondary conjugated antibodies (anti-human IgA-APC (Miltenyi Biotec) and anti-human IgG-APC/Cy7 (BioLegend) or their respective isotype controls. Samples were fixed with 0.75% v/v paraformaldehyde. Acquisition of cellular events was performed using the BD LSRFortessaTM (BD Biosciences) and analysed using FlowJoTM software. Frequencies of antibody bound stool microbes were expressed as percentages. The percentage of Ig-bound microbes was normalised by subtracting frequency of Ig-bound microbes measured using isotype controls.

Metagenomic shotgun sequencing analysis of total gut microbiota and IgG-coated microbes (IgG-Seq)

Microbial cell sorting

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

Non-diluted stool samples were processed and stained for IgG flow cytometry analysis as described previously. Isotype controls were not used in microbial cell sorting. Microbes were diluted to 1 x 10⁷ cells/ml and cell sorting achieved using the Sony SH800S cell sorter equipped with four lasers: 488 nm, 405nm, 638nm and 651nm. Prior to sample acquisition the instrument was cleaned and calibrated according to the manufacturer's instructions. Microbes (1 x 10⁶) were collected from the following three fractions: 1) 'all' (SYBR⁺ microbes), 2) 'IgG positive' (SYBR⁺IgG⁺), 3) 'IgG negative' (SYBR⁺IgG⁻). Fractions were centrifuged and immediately stored at -20°C as dry pellets. DNA extraction, processing and sequencing DNA was extracted using the Gram-positive bacteria genomic DNA purification protocol from the GeneJET DNA genomic DNA purification kit (Thermoscientific) with the following modifications: 1) 0.52 kU/ml achromopeptidase was added to the lysis buffer and the incubation time increased to 60 min; 2) incubation with lysis solution and proteinase K was increased to 50 min. DNA was precipitated using 0.7X solid phase reversible immobilisation bead clean-up with KAPA pure beads (Roche). Whole genome amplification was performed using the REPLI-g advanced DNA single cell kit (QIAGEN). The quality and quantity of amplified genomic DNA were determined using the Agilent Tapestation 4200 and the Quanti-iTTM dsDNA high sensitivity assay kit (Thermo Fisher Scientific). A ready-to-load pooled sequencing library was prepared by the in-house QIB sequencing service using the Illumina DNA prep kit (Illumina, 20018704) and the KAP2G Robust PCR kit (Sigma), followed by sequencing using 2 x 150 bp paired-end chemistry (PE150) on the Illumina NovaSeq 6000 platform (Novogene Ltd., UK). Paired-end sequencing reads were provided as FASTQ format. All raw sequencing reads were pre-processed using tools retrieved from the BioConda repository⁴¹. SeqFu (v1.8.5) ⁴² was used to assess the quality of raw sequencing reads and those bases below Phred quality score of 15 were removed using Fastp (v0.20.0) ⁴³. Human genomic DNA identified by Kraken2⁴⁴ against the Genome Reference Consortium Human Build 37 (GRCh37/hg19) database were removed. Taxonomic assignment of remaining sequencing reads was done using Kraken2⁴⁴ against the 'PlusPF' database containing archaea, bacteria, viral, plasma, human1, UniVec_Core, Protozoa and Fungi https://benlangmead.github.io/aws-indexes/k2. Abundance of reads at the species level was estimated using Bracken⁴⁵. Taxonomic read counts were converted to relative abundances by total sum scaling to 1.

Relative and quantitative microbiome profiling

The 'all' fraction from microbial cell sorting was used for relative microbiome profiling (RMP) and quantitative microbiome profiling (QMP). The cut off threshold of 1 x 10^{-6} was applied to relative abundances and a pseudocount of 1 x 10^{-7} was added. The microbial load of each species was calculated on these modified relative abundances using the equation below.

absolute abundance $(cells/g)_{ij} = RA_{ij} \times total\ cell\ concentration\ (cells/g)_{j}$

Analysing IgG binding of taxa

RMP data was used for IgG binding analysis with a cut off threshold of 1 x 10^{-5} . In addition, for each participant if a species was not detected in the 'all' fraction above the threshold then this species was subsequently removed from respective 'IgG positive' and 'IgG negative' fractions. The 'IgAScores' (v.0.1.2) ²⁵ R package was used to calculate IgG probability ratios using the 'igascores' function with method set to 'probratio', pseudocount 'c' set to 1 x 10^{-5} and 'scaleratio' set to TRUE.

$$probability\ ratio_{ij} = log2 \left(\frac{\left(IgG_{ij}^{+} \times Fraction\ size_{j}^{IgG+} \right) + c}{\left(IgG_{ij}^{-} \times Fraction\ size_{j}^{IgG-} \right) + c} \right)$$

Alpha diversity

The diversity function from the 'vegan' R package (v.2.5-7)⁴⁶ was used to calculate Shannon indices and inverse Simpson indices. The rarefy function from 'vegan' (v.2.5-7)⁴⁶ was used to rarefy reads to the lowest sequencing depth. Observed species' richness was the number of species remaining following rarefaction.

Beta diversity

The vegdist function from 'vegan' (v.2.5-7) ⁴⁶ was used to calculate Bray-Curtis indices on relative abundances. The metMDS function from 'vegan' (v.2.5-7) ⁴⁶ was used to performed non-metric multidimensional scaling (NDMS) on Bray-Curtis indices.

Functional analysis

Gene families were identified using the HMP Unified Metabolic Analysis Network 3.0 (HUMAnN 3.0) package from the bioBakery suite^{47,48}. In all participants each gene family was filtered by the following criteria: if a gene family was not present in the 'all' fraction the reads per kilobase (RPK) were zeroed in the 'IgG positive' and 'IgG negative' fractions of that participant. The humann_renorm_table utility script from HUMAnN 3.0 was used to convert gene families from RPK to relative abundances. Community level classifications of gene families were used in downstream analysis. A cut off threshold of 1 x 10⁻⁶ was applied to all samples.

To analyse gene families in the microbiome of severe ME/CFS patients compared with household controls the 'all' fraction was used. Gene families that were below the threshold in seven or more samples were discarded from downstream analysis. The clr

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

function from the 'compositions' R package (v 2.0-4) 49 was used to CLR transform the relative abundance of gene families. The pca function from the 'mixOmics' R package (v 6.18.1) 50 was used to perform principal component analysis (PCA) on gene families. Severe ME/CFS patients and their matched household controls were not treated as paired samples in this analysis. To analyse gene families of IgG reactive microbes IgG probability ratios were calculated using the relative abundance of gene families in the 'IgG positive' fraction and the 'IgG negative' fraction as described earlier, with a pseudocount set to 6 x 10. Gene families that did not have IgG probability ratios in all samples were discarded from downstream analysis. PCA was then performed as described previously. Statistical analysis Statistical analyses and graphical representations were performed in R using the following packages: 'ggplot2' (v3.4.0) 51, 'reshape2' (v1.4.4) 52, 'data.table' (v1.14) 53, 'dplyr' (v1.1.0) ⁵⁴, 'ggpubr' (V0.5.0) ⁵⁵. Graphs were also made using GraphPad Prism 5.04. Prior to analysis data were log-transformed if there was evidence for non-normality. Pairwise comparisons between severe ME/CFS patients and their matched household controls were done using a two-tailed paired t-test. Correlations were assessed with Pearson (r) correlation test. Common data elements for ME research This study used the National Institute of Neurological Disorders and Stroke Common Data Elements guidelines' for reporting microbiome/microorganisms biomarkers in ME/CFS research (http://www.commondataelements.ninds.nih.gov/)⁵⁶. Acknowledgements

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

We acknowledge East Coast Community Healthcare ME/CFS service and the CFS clinic at Epsom and St Helier University Hospitals NHS Trust for their help recruiting patients, the QIB Human Research Governance Committee (HRGC) for reviewing the HRA application and all the research participants who generously shared their time. KAS was supported by a PhD studentship jointly funded by Invest in ME Research (UK charity number 1153730) and the University of East Anglia. The authors gratefully acknowledge the support of the Biotechnology and Biological Sciences Research Council (BBSRC); The authors gratefully acknowledge the support of the Biotechnology and Biological Sciences Research Council (BBSRC); this research was supported by the BBSRC Institute Strategic Programme Grant Gut Microbes and Health BB/R012490/1 and its constituent projects BBS/E/F/000PR10353 and BBS/E/F/000PR10355 (SRC). MD and GS were funded by the BBSRC Core Capability Grant BB/CCG1860/1. **Declaration of interest statement** The authors report there are no competing interests to declare. Data availability statement The raw WMS data are available at the European Nucleotide Archive under study accession PRJEB61661. (http://www.ebi.ac.uk/ena/broswer/view/PRJEB61661).

References

586

610

587 Lim EJ, Son CG. Review of case definitions for myalgic encephalomyelitis/chronic 588 fatigue syndrome (ME/CFS). J. Transl. Med. 2020;18:289. doi: 10.1186/s12967-020-589 02455-0. PMID: 32727489. 590 2 Pendergrast T, Brown A, Sunnquist M, Jantke R, Newton JL, Strand EB, Jason LA. Housebound versus nonhousebound patients with myalgic encephalomyelitis and 591 592 chronic fatigue syndrome. Chronic Illn. 2016;12:292-307. doi: 10.1177/1742395316644770. PMID: 27127189. 593 594 3 Chu L, Valencia IJ, Garvert DW, Montoya, JG. Onset Patterns and Course of Myalgic 595 Encephalomyelitis/Chronic Fatigue Syndrome. Front Pediatr. 2019;7:12. doi: 596 10.3389/fped.2019.00012. PMID: 30805319. 597 4 Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-598 analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis 599 (CFS/ME). J. Transl. Med. 2020;18:100. doi: 10.1186/s12967-020-02269-0. PMID: 600 32093722. 601 5 Salari N, Khodayari Y, Hosseinian-Far A, Zarei H, Rasoulpoor S, Akbari H, 602 Mohammadi M. Global prevalence of chronic fatigue syndrome among long COVID-603 19 patients: A systematic review and meta-analysis. Biopsychosoc. Med. 2022;16:21. 604 doi: 10.1186/s13030-022-00250-5. PMID: 36274177. Missailidis D, Annesley SJ, Fisher, PR. Pathological Mechanisms Underlying 605 6 606 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Diagnostics 607 2019;9:80. doi: 10.3390/diagnostics9030080. PMID: 31330791. 608 7 Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with 609 chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch.

Intern. Med. 2000;160:221-227. doi: 10.1001/archinte.160.2.221. PMID: 10647761.

611	8	Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced
612		diversity and altered composition of the gut microbiome in individuals with myalgic
613		encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016;4:30. doi:
614		10.1186/s40168-016-0171-4. PMID: 27338587.
615	9	Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG,
616		Komaroff AL, Levine S, Montoya JG, et al. Fecal metagenomic profiles in subgroups
617		of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome.
618		2017;5:44. doi: 10.1186/s40168-017-0261-y. PMID: 28441964.
619	10	Armstrong CW, McGregor NR, Lewis DP, Butt HL, Gooley PR. The association of
620		fecal microbiota and fecal, blood serum and urine metabolites in myalgic
621		encephalomyelitis/chronic fatigue syndrome. Metabolomics. 2016;13:8. doi:
622		10.1007/s11306-016-1145-z.
623	11	Xiong R, Gunter C, Fleming E, Vernon SD, Bateman L, Unutma. Multi-'omics of gut
624		microbiome-host interactions in short- and long-term myalgic
625		encephalomyelitis/chronic fatigue syndrome patients. Cell Host Microbe.
626		2023;31:273-287.e275. doi: 10.1016/j.chom.2023.01.001. PMID: 36758521.
627	12	Guo C, Che X, Briese T, Ranjan A, Allicock O, Yates RA, Cheng A, March D,
628		Hornig M, Komaroff AL et al. Deficient butyrate-producing capacity in the gut
629		microbiome is associated with bacterial network disturbances and fatigue symptoms
630		in ME/CFS. Cell Host Microbe. 2023;31:288-304.e288. doi:
631		10.1016/j.chom.2023.01.004. PMID: 36758522.
632	13	Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of
633		enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of
634		gram-negative enterobacteria in the etiology of CFS and for the presence of an

635		increased gut-intestinal permeability. J. Affect. Disord. 2007;99:237-240. doi:
636		10.1016/j.jad.2006.08.021. PMID: 17007934.
637	14	Shukla SK, Cook D, Meyer J, Vernon SD, Le T, Clevidence D, Robertson CE,
638		Schrodi SJ, Yale S, Frank DN. Changes in Gut and Plasma Microbiome following
639		Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
640		(ME/CFS). PLoS One. 2015; 10 :e0145453. doi: 10.1371/journal.pone.0145453.
641		PMID: 26683192.
642	15	Duchmann R, Neurath MF, Meyer zum Büschenfelde KH. Responses to self and non-
643		self intestinal microflora in health and inflammatory bowel disease. Res. Immunol.
644		1997;148:589-594. doi: 10.1016/s0923-2494(98)80154-5. PMID: 9588839.
645	16	Harmsen HJ, Pouwels SD, Funke A, Bos NA, Dijkstra G. Crohn's disease patients
646		have more IgG-binding fecal bacteria than controls. Clin. Vaccine Immunol.
647		2012;19:515-521. doi:10.1128/cvi.05517-11. PMID: 22336288.
648	17	Ruff WE, Greiling TM, Kriegel MA. Host-microbiota interactions in immune-
649		mediated diseases. Nat. Rev. Microbiol. 2020;18:521-538. doi: 10.1038/s41579-020-
650		0367-2. PMID: 32457482.
651	18	Maes M, Ringel K, Kubera M, Anderson G, Morris G, Galecki P, Geffard M. In
652		myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity
653		against 5-HT is associated with immuno-inflammatory pathways and bacterial
654		translocation. J. Affect. Disord. 2013;150:223-230. doi: 10.1016/j.jad.2013.03.029.
655		PMID: 23664637.
656	19	Quigley EMM. Gut bacteria in health and disease. Gastroenterol Hepatol (N Y).
657		2013;9:560-569. PMID: 24729765.

658 20 Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, Function, and 659 Therapeutic Use of IgM Antibodies. Antibodies (Basel). 2020;9:53. doi: 660 10.3390/antib9040053. PMID: 33066119. 21 661 de Sousa-Pereira P, Woof JM. IgA: Structure, Function, and Developability. 662 Antibodies (Basel). 2019;8:57. doi: 10.3390/antib8040057. PMID: 31817406. 663 22 Vogl T, Kalka IN, Klompus S, Leviatan S, Weinberger A, Segal E. Systemic antibody 664 responses against human microbiota flagellins are overrepresented in chronic fatigue 665 syndrome patients. Sci Adv. 2022;8:eabq2422. doi: 10.1126/sciadv.abq2422. PMID: 666 36149952. 667 23 Vogl T, Klompus S, Leviatan S, Kalka IN, Weinberger A, Wijmenga C, Fu J, 668 Zhernakova A, Weersma RK, Segal E. Population-wide diversity and stability of 669 serum antibody epitope repertoires against human microbiota. Nat. Med. 670 2021;27:1442-1450. doi: 10.1038/s41591-021-01409-3. PMID: 34282338. 671 24 Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L, Degnan PH, 672 Hu J, Peter I, Zhang W, et al. Immunoglobulin A coating identifies colitogenic 673 inflammatory bowel disease. Cell. 2014;158:1000-1010. 674 10.1016/j.cell.2014.08.006. PMID: 25171403. 675 25 Jackson MA, Pearson C, Ilott NE, Huus KE, Hegazy AN, Webber J, Finlay BB, 676 Macpherson AJ, Powrie F, Lam LH. Accurate identification and quantification of 677 commensal microbiota bound by host immunoglobulins. Microbiome. 2021;9:33. 678 doi: 10.1186/s40168-020-00992-w. PMID: 33516266. 679 26 Redondo-Useros N, Nova E, González-Zancada N, Díaz LE, Gómez-Martínez S, 680 Marcos A. Microbiota and Lifestyle: A Special Focus on Diet. Nutrients. 681 2020;12:1776. doi: 10.3390/nu12061776. PMID: 32549225.

682 27 Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen MAY, Bolte LA, Andreu-683 Sánchez S, Chen L, Collij V, Hu S et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature. 2022;604:732-739. doi:10.1038/s41586-684 685 022-04567-7. PMID: 35418674. 686 28 Lupo GFD, Rocchetti G, Lucini L, Lorusso L, Manara E, Bertelli M, Puglisi E, 687 Capelli E. Potential role of microbiome in Chronic Fatigue Syndrome/Myalgic Encephalomyelits (CFS/ME). Sci. Rep. 2021;11:7043. doi: 10.1038/s41598-021-688 689 86425-6. PMID: 33782445. 690 29 Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 691 2016;16:626-638. doi:10.1038/nri.2016.90. PMID: 27546235. 692 30 Milan-Mattos JC, Anibal FF, Perseguini NM, Minatel V, Rehder-Santos P, Castro 693 CA, Vasilceac FA, Mattiello SM, Faccioli LH, Catai AM. Effects of natural aging and 694 gender on pro-inflammatory markers. Braz J Med Biol Res. 2019;52:e8392. doi: 695 10.1590/1414-431x20198392. PMID: 31411315. 696 31 Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y. Host variables 697 confound gut microbiota studies of human disease. Nature, 2020;587:448-454. doi: 698 10.1038/s41586-020-2881-9. PMID: 33149306. 699 32 Lax S, Smith DP, Hampton-Marcell J, Owens SM, Handley KM, Scott NM, Gibbons 700 SM, Larsen P, Shogan BD, Weiss S, et al. Longitudinal analysis of microbial 701 interaction between humans and the indoor environment. Science, 2014:345:1048-702 1052. doi: 10.1126/science.1254529. PMID: 25170151. 703 33 Guenther S, Loebel M, Mooslechner AA, Knops M, Hanitsch LG, Grabowski P, 704 Wittke K, Meisel C, Unterwalder N, Volk HD, et al. Frequent IgG subclass and 705 mannose binding lectin deficiency in patients with chronic fatigue syndrome. Hum. 706 Immunol. 2015;76:729-735. doi: 10.1016/j.humimm.2015.09.028. PMID: 26429318.

707 34 Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME, 708 Zareian N, Accardi G. Immunosenescence and Its Hallmarks: How to Oppose Aging 709 Strategically? A Review of Potential Options for Therapeutic Intervention. Front. 710 Immunol. 2019;10:2247. doi: 10.3389/fimmu.2019.02247. PMID: 31608061. 711 35 Eaton-Fitch N, du Preez S, Cabanas H, Staines D, Marshall-Gradisnik S. A systematic 712 review of natural killer cells profile and cytotoxic function in myalgic 713 encephalomyelitis/chronic fatigue syndrome. Syst Rev. 2019;8:279. 714 doi:10.1186/s13643-019-1202-6. PMID: 31727160. 715 36 Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L, Baxter A, Nathan 716 N, Anderson W, Gordon E. Metabolic features of chronic fatigue syndrome. Proc. 717 Natl. Acad. Sci. U. S. A. 2016;113:E5472-5480. doi: 10.1073/pnas.1607571113. 718 PMID: 27573827. 719 37 Morris G, Maes M, Berk M, Puri BK. Myalgic encephalomyelitis or chronic fatigue 720 syndrome: how could the illness develop? Metab. Brain Dis. 2019;34:385-415. doi: 721 10.1007/s11011-019-0388-6. PMID: 30758706. 722 38 Baker R, Shaw EJ. Diagnosis and management of chronic fatigue syndrome or 723 myalgic encephalomyelitis (or encephalopathy): summary of NICE guidance. BMJ. 724 2007;335:446-448. doi: 10.1136/bmj.39302.509005.AE. PMID: 17762037. 725 39 Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic 726 fatigue syndrome: a comprehensive approach to its definition and study. International 727 Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-9. doi: 728 10.7326/0003-4819-121-12-199412150-00009. PMID: 7978722. 729 40 Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. 730 Scand J Gastroenterol. 1997;32:920-4. doi: 10.3109/00365529709011203. PMID: 731 9299672.

- Grüning B, Dale R, Sjödin A, Chapman BA, Rowe J, Tomkins-Tinch CH, Valieris R,
- 733 Köster J; Bioconda Team. Bioconda: sustainable and comprehensive software
- 734 distribution for the life sciences. Nat Methods. 2018;15:475-476. doi:
- 735 10.1038/s41592-018-0046-7. PMID: 29967506.
- 736 42 Telatin A, Fariselli P, Birolo G. SeqFu: A Suite of Utilities for the Robust and
- 737 Reproducible Manipulation of Sequence Files. Bioengineering (Basel). 2021;8:59.
- doi: 10.3390/bioengineering8050059. PMID: 34066939.
- 739 43 Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
- Bioinformatics. 2018;34:i884-i890. doi: 10.1093/bioinformatics/bty560. PMID:
- 741 30423086.
- 742 44 Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2.
- 743 Genome Biol. 2019;20:257. doi: 10.1186/s13059-019-1891-0. PMID: 31779668.
- Lu J, Breitwieser FP, Thielen P, Salzberg SL. Bracken: estimating species abundance
- in metagenomics data. PeerJ Computer Science. 2017;3:e104. doi: 10.7717/peerj-
- 746 cs.104
- 747 46 Oksanen J, Simpson GL, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'Hara
- RB, Solymos P, Stevens MHH, Szoecs E, et al. _vegan: Community Ecology
- Package_. R package version v.2.6-4. 2022. https://CRAN.R-
- 750 project.org/package=vegan>.
- 751 47 Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan
- 752 A, Manghi P, Scholz M, Thomas AM, et al. Integrating taxonomic, functional, and
- strain-level profiling of diverse microbial communities with bioBakery 3. Elife.
- 754 2021;10:e65088. doi: 10.7554/eLife.65088. PMID: 33944776.

- 755 48 McIver LJ, Abu-Ali G, Franzosa EA, Schwager R, Morgan XC, Waldron L, Segata N,
- Huttenhower C. bioBakery: a meta'omic analysis environment. Bioinformatics.
- 757 2018;34:1235-1237. doi: 10.1093/bioinformatics/btx754. PMID: 29194469.
- van den Boogaart KG, Tolosana-Delgado R, Bren M. _compositions: Compositional
- 759 Data Analysis_. R package version 2.0-6. 2023. https://CRAN.R-
- 760 project.org/package=compositions>.
- 761 50 Rohart F, Gautier B, Singh A, Lê Cao KA. mixOmics: An R package for 'omics
- feature selection and multiple data integration. PLoS Comput Biol.
- 763 2017;13:e1005752. doi: 10.1371/journal.pcbi.1005752. PMID: 29099853.
- 764 51 Wickham, H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-
- 765 Verlag; 2016.
- Wickham, H. Reshaping Data with the reshape Package. J Stat Soft. 2007;21:1-20.
- 767 doi: 10.18637/jss.v021.i12.
- Dowle M, Srinivasan A. _data.table: Extension of `data.frame`_. R package version
- 769 1.14.6. 2022. https://CRAN.R-project.org/package=data.table>.
- 770 54 Wickham H, François R, Henry L, Müller K, Vaughan D. dplyr: A Grammar of Data
- 771 Manipulation_. R package version 1.1.0. 2023. https://CRAN.R-
- 772 project.org/package=dplyr>.

- 773 55 Alboukadel K. ggpubr: 'ggplot2' Based Publication Ready Plots . R package version
- 774 0.6.0. 2023. https://CRAN.R-project.org/package=ggpubr>.
- 775 56 Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National
- 776 Institute of Neurological Disorders and Stroke Common Data Element Project -
- approach and methods. Clin Trials. 2012;9:322-329. doi:
- 778 10.1177/1740774512438980. PMID: 22371630.

Table 1. Severe ME/CFS clinical characteristics

	Participants affected (%)	Mean (SD)	Range
Age of ME/CFS onset (years)	-	25.0 (9.34)	12-38
Length of ME/CFS (years)	-	8.4 (6.83)	2-21
Symptoms			
Post exertional malaise	100	-	-
Non-restorative sleep	100	-	-
Headaches of a new onset, pattern and severity	80	-	-
Recurrent sore throat with enlarged glands in neck	40	-	-
Impaired concentration	100	-	-
Impaired memory	80	-	-
Joint pain	60	-	-
Muscle pain	80	-	-
Visual and/or auditory hypersensitivity	100	-	-
Irritable bowel syndrome	100	-	-
Questionnaire (maximum score)			
Shortened SF-36 (30) *	-	11.0 (1.73)	10-14
Chalder fatigue – physical (28) *	-	24.0 (3.67)	18-27
Chalder fatigue – mental (16) *	-	13.5 (1.12)	12-15
HADS – anxiety (21) *	-	7.8 (4.55)	3-15
HADS – depression (21) *	-	6.5 (5.50)	3-16

Self efficacy (60) **	-	12.0 (7.35)	3-21
Visual analogue (100) *	-	62.5 (36.31)	0-90
Epworth sleepiness (24) ***	-	7.5 (14)	1-14

^{*} questionnaire completed by 4 patients ** questionnaire completed by 3 patients

^{***} questionnaire completed by 2 patients

Table 2. Proportion of species detected that are recognised by serum IgG

Pair	Participant	Number of species detected per fraction			Proportion of species	
	-	Only IgG-	Only IgG+	Both IgG- and IgG+	- IgG+	
1	Patient	7	7	201	0.967	
	Control	23	7	173	0.887	
2	Patient	18	7	190	0.916	
	Control	21	6	202	0.908	
3	Patient	107	4	154	0.596	
	Control	14	12	145	0.918	
4	Patient	4	19	138	0.975	
	Control	29	6	168	0.857	
5	Patient	9	18	162	0.952	
	Control	15	31	206	0.940	

SUPPLEMENTARY TABLE 1. The size of IgG positive and IgG negative fractions

collected during IgG-Seq. This data was used to calculation of IgG probability ratio scores.

Pair	Participant	Fraction sizes (%)	
	_	IgG+	IgG-
1	Patient	21.1	79.5
	Control	18.0	79.8
2	Patient	35.1	58.1
	Control	48.1	49.7
3	Patient	17.9	65.5
	Control	46.3	44.9
4	Patient	65.0	29.0
	Control	33.7	63.1
5	Patient	24.2	75.3
	Control	62.7	31.1

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

FIGURE 1. Stool consistency. (A) Analysis of stool consistency using the Bristol stool form scale (BSFS) in severe ME/CFS patients (n=5) and matched household controls (n=5). P values were calculated using a two-tailed paired t-test. (B) Water content in stool samples in severe ME/CFS patients (n=5) and matched household controls (n=5). P values were calculated using a two-tailed paired t-test. FIGURE 2. Concentration of IgA measured by ELISA in the stool of severe ME/CFS patients (n=5) and matched household controls (n=5) for (A) microbe bound IgA, and (B) microbe non-bound IgA. For both plots p values were calculated using a two-tailed paired t-test. FIGURE 3. Profiling stool IgA. (A) Overview of sample preparation for IgA-bound microbe fluorescent activated cell sorting (FACS) analysis. (B) Representative flow cytometric analysis of IgA-bound stool microbes. (C) Proportion of stool microbes bound by IgA in severe ME/CFS patients (n=5) and matched household controls (n=5). P values were calculated using a two-tailed paired t-test. (D) Analysis of IgA-bound microbial load in severe ME/CFS patients (n=5) and matched household controls (n=5). P values were calculated using a two-tailed paired t-test. FIGURE 4. Serum IgG reactivity to autologous and heterologous stool microbes. (A) Overview of assessment of IgG responses to indigenous (autologous) and foreign (heterologous) stool microbes in severe ME/CFS patients and matched healthy household controls. (B) Level of IgG in serum of severe ME/CFS patients (n=5) and household control (n=5) binding to stool microbes from patient and control stool samples in vitro. (C) Levels of

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

IgG in serum of severe ME/CFS patients (n=5) and their matched household controls quantified by ELISA (n=5). Two-tailed paired t-tests were used to calculate P values. FIGURE 5. Quantifying stool microbes recognised by autologous serum IgG. (A) Overview of sample preparation for IgG-bound microbe FACS analysis. (B) Representative analysis of serum IgG binding to stool microbes. (C) Analysis of the proportion of stool microbes bound by serum IgG in severe ME/CFS patients (n=5) and matched household controls (n=5). P values were calculated using a two-tailed paired t-test. FIGURE 6. IgG-Seq. (A) IgG-Seq protocol used to determine taxa from stool samples reactive to autologous serum IgG. (B) Representative flow cytometric dot plot showing IgG-Seq gating strategy based upon forward scatter (FSC) and back scatter (BSC) characteristics, followed by discrimination of singlets from doublets. SYBR+ microbes were discriminated from auto fluorescent debris and collected for profiling of all stool microbes. IgG positive and IgG negative populations were sorted from SYBR+ events. (C) Pairwise comparisons of observed richness of IgG positive and IgG negative microbes in severe ME/CFS patients (n=5) and matched household controls (n=5). Analyses were performed at the species-level reads rarefied to the lowest sequencing depth. P values were measured using two-tailed paired t-tests. (D) Beta diversity of IgG positive species (filled shapes) and IgG negative species (unfilled shapes) in severe ME/CFS patients (circles) and household controls (squares). Beta-diversity was calculated using Bray-Curtis dissimilarity, presented on a nonmetric multi-dimensional scaling (NMDS) plot.

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857


858

FIGURE 7. Probability of serum IgG binding to autologous stool microbes from severe ME/CFS patients (n=5) and matched household controls (n=5). IgG probability ratios for species detected in all participants stool samples. SUPPLEMENTARY FIGURE 1. Study participant recruitment pathway. Severe ME patients were recruited from the CFS clinic at Epsom and St Helier University Hospitals (ESTH), Carshalton, UK and the ME/CFS service at East Coast Community Healthcare Centre, Lowestoft, UK. SUPPLEMENTARY FIGURE 2. Stool microbial load. Flow cytometric analysis of SYBR Green+ microbial load in stool samples of severe ME/CFS patients (n=5) and matched household controls (n=5). SUPPLEMENTARY FIGURE 3. Stool microbiome profiling of severe ME/CFS patients (n=5) and matched household controls (n=5). (A) Relative microbiome profiling (RMP) at the genus-level. (B) quantitative microbiome profiling (QMP, cells per gram of faeces) at the genus-level. (C) RMP at the species-level. (D) QMP at the species-level. SUPPLEMENTARY FIGURE 4. Pairwise alpha- and beta-diversity comparisons of the stool microbiomes of severe ME/CFS patients (n=5) and matched household controls (n=5). Analyses were performed at the species-level on shotgun metagenomics data from SYBR+ stool microbes. (A) Alpha diversity measures of Shannon index, inverse Simpson index and richness based on reads rarefied to the lowest sequencing depth. P values were measured


using two-tailed paired t-tests. (B) Beta diversity of relative microbiome profiling (RMP) and quantitative microbiome profiling (QMP, cells per gram faeces). Beta-diversity was calculated using Bray-Curtis dissimilarity, presented on a non-metric multi-dimensional scaling (NMDS) plot.


SUPPLEMENTARY FIGURE 5. Functional composition of stool metagenomes from severe ME/CFS patients (circles) (n=5) and matched household controls (squares) (n=5). Principal component analysis (PCA) of the relative abundances of gene families. Pair numbers are depicted on the graph but were not used in analysis.


SUPPLEMENTARY FIGURE 6. Functional profiling of stool microbes reactive with serum IgG. Principal component analysis (PCA) of IgG probability ratios of gene families from the stool microbiome in severe ME/CFS patients (circles) (n=5) and matched household controls (squares) (n=5). Pair numbers are depicted on the graphs but were not used in analysis.





A

















Sybr

B

IgG negative Δ

